PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data ...
Clinical-stage PTK7 ADC KIVU-107 shows strong preclinical anti-tumor activity, favorable pharmacokinetics and improved tolerability Next-generation CEACAM5 ADC KIVU-305 demonstrates potent preclinical ...
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...
SEATTLE--(BUSINESS WIRE)--ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the ...
This novel approach utilizes cysteine-engineered antibodies which allows for the development of uniform and homogenous ADCs with precise control of the drug to antibody ratio (DAR). The drug-payload, ...
New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct to address one of oncology’s most challenging and valuable solid tumor targets, ...
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, ...
PRAGUE & BEIJING--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the licensing of fully human antibodies from Biocytogen (HKEX: 02315), ...
Ideaya Biosciences Inc. bought global rights to Biocytogen Pharmaceuticals Co. Ltd.’s cancer-targeting bispecific antibody-drug conjugate (bsADC) program in a deal reaching up to $406.5 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results